🧬 Liddle's syndrome is a rare inherited cause of secondary hypertension.
It presents with hypokalaemic hypertension, metabolic alkalosis, and suppressed renin + aldosterone levels — hence termed “pseudo-hyperaldosteronism”.
About 🔎
- Liddle's syndrome: Autosomal dominant genetic disorder.
- Mutation in the ENaC (Epithelial Sodium Channel) of the renal collecting ducts ➝ excessive sodium reabsorption ➝ hypertension.
- Potassium wasting causes hypokalaemia, weakness, and arrhythmia risk.
- Very rare but important to recognise in young patients with resistant hypertension.
Clinical Features 🧑⚕️
- 📈 Hypertension: Early onset, often severe.
- 💤 Weakness & Fatigue: From hypokalaemia.
- ⚡ Muscle cramps: Due to low potassium and metabolic alkalosis.
- 🌙 Nocturia & Polyuria: From impaired renal concentrating ability.
- 🫀 Arrhythmias: Severe hypokalaemia may trigger dangerous cardiac rhythms.
Investigations 🧪
- 🟢 Serum Potassium: Low (hypokalaemia).
- 🟢 ABG: Metabolic alkalosis.
- 🔻 Plasma Renin Activity: Suppressed.
- 🔻 Aldosterone: Suppressed (distinguishes from Conn’s syndrome).
- 🧬 Genetic Testing: Can confirm ENaC mutation.
Differential Diagnosis 🔍
- Conn’s Syndrome (Primary Hyperaldosteronism): Both present with hypertension + hypokalaemia, but Conn’s has high aldosterone levels, while Liddle’s has low aldosterone.
- Apparent Mineralocorticoid Excess (AME): Enzyme defect (11β-HSD2) or liquorice ingestion; also causes pseudo-hyperaldosteronism but via cortisol effect on mineralocorticoid receptors.
Management 💊
- 🥗 Low Sodium Diet: First-line to reduce hypertension.
- 💊 Amiloride or Triamterene: Block ENaC directly ➝ correct hypertension and hypokalaemia.
- ❌ Spironolactone ineffective: Because aldosterone is already low; mechanism is sodium channel mutation, not aldosterone excess.
- 👀 Lifelong treatment is usually required, with good prognosis if controlled.
Exam Clinical Pearl ✨
If you see a young patient with hypertension, hypokalaemia, metabolic alkalosis and low renin & aldosterone ➝ think **Liddle’s syndrome**.
Treatment is with amiloride, not spironolactone.
Cases — Liddle’s Syndrome
- Case 1 — Young-onset hypertension 🧑: A 19-year-old man is found to have BP 170/105 mmHg during a routine sports medical. Bloods: low potassium, metabolic alkalosis, suppressed renin and aldosterone. Family history: father with early stroke. Diagnosis: Liddle’s syndrome (ENaC overactivity causing pseudohyperaldosteronism). Managed with amiloride (ENaC blocker) and salt restriction.
- Case 2 — Resistant hypertension 💊: A 24-year-old woman presents with persistent high BP despite triple therapy including ACE inhibitor, calcium-channel blocker, and thiazide. Labs: K⁺ 2.8 mmol/L, HCO₃⁻ 31 mmol/L, suppressed renin and aldosterone. Diagnosis: Liddle’s syndrome with resistant hypertension. Treated with triamterene/amiloride; spironolactone ineffective as aldosterone is suppressed.
- Case 3 — Childhood presentation 👦: A 12-year-old boy is referred with growth retardation, polyuria, and muscle weakness. Exam: hypertension (150/95). Labs: hypokalaemia, metabolic alkalosis, low renin and aldosterone. Genetic testing confirms ENaC mutation. Diagnosis: paediatric Liddle’s syndrome. Managed with ENaC blockers and nephrology follow-up.
Teaching Point 🩺: Liddle’s syndrome is a rare autosomal dominant disorder causing constitutive activation of epithelial sodium channels (ENaC). This leads to sodium retention, hypertension, hypokalaemic metabolic alkalosis, suppressed renin and aldosterone. Key clue: it mimics hyperaldosteronism but does not respond to spironolactone — instead, amiloride/triamterene are effective.